Sanofi/GSK New Crown Vaccine Launches Human Clinical Trial Phase 3 Trials expected to begin by the end of the year.

According to the latest statistics of the World Health Organization (WHO), there are currently 34 candidates for the new crown vaccine into clinical development.
four of the candidate vaccines are recombinal protein vaccines.
COVID-19 vaccine, developed jointly by Sanofi and GlaxoSmithKline, is one of them.
Recombination Protein Vaccine Technology Platform supports large-scale expression of recombined new coronavirus S proteins by transfection of insect cells using Baculovirus.
flu vaccine Flublock, which has been approved by the U.S. FDA, is based on this production platform.
of recombined protein candidate vaccines is that they are stable and can be stored and transported at 2-8 degrees C.
, Sanofi and GSK reached a partnership to provide its adulent technology for this candidate vaccine.
the technology not only enhances the immunogenicity of the vaccine, but also reduces the amount of vaccine protein needed for each dose of vaccine, allowing more vaccines to be produced to help patients in need.
preclinical data show that two injections of the advent recombinant vaccine can stimulate high levels of meso-antibodies, comparable to among patients recovering from COVID-19.
results will be published later this year.
Sanofi/GSK New Crown Candidate Vaccine Research and Development Program (Photo: Sanofi.com) This Phase 1/2 clinical trial is a randomized double-blind, placebo-controlled study designed to assess the safety, reactogenity, and immunogenicity of coVID-19 candidate vaccines.
program includes 440 healthy adult volunteers at 11 research centers.
in the first phase of the trial, the volunteers were between the ages of 18 and 49.
, the trial will recruit a wider range of volunteers, including at least 140 over the age of 50.
company expects the first results to be obtained in early December 2020 to support the launch of Phase 3 clinical trials by December 2020.
if the data is sufficient to apply for a permit, it plans to apply for regulatory approval in the first half of 2021.
same time, Sanofi and GSK are expanding production of antigens and adjeers, with the goal of producing up to 1 billion doses of vaccine candidates by 2021.
: sanofi and GSK' Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-base vaccine candidate. Retrieved September 3, 2020, from .2, Landscape Draft of COVID-19 candidate vaccines. Retrieved September 3, 2020, from sanofi and GSK move Covid-19 vaccine into human trials. Retrieved September 3, 2020, from.